At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PCVX Vaxcyte, Inc.
Pre-Mkt 03-10 05:20:13 EDT
59.32
+0.03
+0.05%
盘前58.90
-0.42-0.71%
04:15 EDT
High60.45Low57.44Vol1.04M
Open58.00D1 Closing59.29Amplitude5.08%
Mkt Cap8.54BTradable Cap6.94BTotal Shares144.00M
T/O60.92MT/O Rate0.89%Tradable Shares116.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
TIPRANKS  ·  03-03
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
Vaxcyte (PCVX) Is Up 5.5% After Unveiling VAX-31 Data, Phase 3 Plans And New Financing - Has The Bull Case Changed?
Simply Wall St.  ·  03-01
Vaxcyte (PCVX) Is Up 5.5% After Unveiling VAX-31 Data, Phase 3 Plans And New Financing - Has The Bull Case Changed?
Stock Track | Vaxcyte, Inc. Plummets 5.05% Intraday on FDA Regulatory Timing Risk Disclosure
Stock Track  ·  02-27
Stock Track | Vaxcyte, Inc. Plummets 5.05% Intraday on FDA Regulatory Timing Risk Disclosure
Vaxcyte Is Maintained at Buy by BTIG
Dow Jones  ·  02-26
Vaxcyte Is Maintained at Buy by BTIG
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
TIPRANKS  ·  02-26
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
TIPRANKS  ·  02-26
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
Vaxcyte price target raised to $89 from $85 at BTIG
TIPRANKS  ·  02-26
Vaxcyte price target raised to $89 from $85 at BTIG
Jefferies Reaffirms Their Buy Rating on Vaxcyte (PCVX)
TIPRANKS  ·  02-25
Jefferies Reaffirms Their Buy Rating on Vaxcyte (PCVX)
Vaxcyte price target lowered to $133 from $134 at BofA
TIPRANKS  ·  02-25
Vaxcyte price target lowered to $133 from $134 at BofA
Stock Track | Vaxcyte Soars 5.09% Intraday on Multiple Analyst Price Target Increases
Stock Track  ·  02-25
Stock Track | Vaxcyte Soars 5.09% Intraday on Multiple Analyst Price Target Increases
Analysts Conflicted on These Healthcare Names: Catalyst Pharma (CPRX), Vaxcyte (PCVX) and Acadia Healthcare (ACHC)
TIPRANKS  ·  02-25
Analysts Conflicted on These Healthcare Names: Catalyst Pharma (CPRX), Vaxcyte (PCVX) and Acadia Healthcare (ACHC)
Vaxcyte price target raised to $75 from $50 at TD Cowen
TIPRANKS  ·  02-25
Vaxcyte price target raised to $75 from $50 at TD Cowen
Vaxcyte Inc : TD Cowen Raises Target Price to $75 From $50
THOMSON REUTERS  ·  02-25
Vaxcyte Inc : TD Cowen Raises Target Price to $75 From $50
BRIEF-Vaxcyte Enters Into Sales Agreement, May Sell Shares Of Common Stock Of Up To $500 Million
Reuters  ·  02-25
BRIEF-Vaxcyte Enters Into Sales Agreement, May Sell Shares Of Common Stock Of Up To $500 Million
Vaxcyte Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  02-25
Vaxcyte Inc reports results for the quarter ended September 30 - Earnings Summary
Vaxcyte Inc - Terminates Open Market Sale Agreement Dated as of July 1, 2021 - SEC Filing
THOMSON REUTERS  ·  02-25
Vaxcyte Inc - Terminates Open Market Sale Agreement Dated as of July 1, 2021 - SEC Filing
Vaxcyte Inc: Entered Into Sales Agreement, May Sell Shares of Common Stock of up to $500 Mln From Time to Time
THOMSON REUTERS  ·  02-25
Vaxcyte Inc: Entered Into Sales Agreement, May Sell Shares of Common Stock of up to $500 Mln From Time to Time
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
TIPRANKS  ·  02-25
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
Vaxcyte posts FY 2025 net loss of USD 766.6 million, up 65.2%
Reuters  ·  02-25
Vaxcyte posts FY 2025 net loss of USD 766.6 million, up 65.2%
Vaxcyte Q4 EPS $(1.80) Misses $(1.56) Estimate
Benzinga  ·  02-25
Vaxcyte Q4 EPS $(1.80) Misses $(1.56) Estimate

Introduction

Company Name.
Vaxcyte, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Issue price:
--